HIV-Associated Lipodystrophy Syndrome - Pipeline Review, Q3 2011

HIV-Associated Lipodystrophy Syndrome - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, Q3 2011', provides an overview of the HIV-Associated Lipodystrophy Syndrome therapeutic pipeline. This report provides information on the therapeutic development for HIV-Associated Lipodystrophy Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-Associated Lipodystrophy Syndrome. 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for HIV-Associated Lipodystrophy Syndrome.
- A review of the HIV-Associated Lipodystrophy Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-Associated Lipodystrophy Syndrome pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for HIV-Associated Lipodystrophy Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-Associated Lipodystrophy Syndrome pipeline depth and focus of HIV-Associated Lipodystrophy Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
HIV-Associated Lipodystrophy Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome
HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Companies
HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Development by Companies
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development
Ark Therapeutics Group plc
Zydus Cadila Healthcare Limited
Theratechnologies Inc.
HIV-Associated Lipodystrophy Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Tesamorelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZYH1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Growth Hormone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avandia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Growth Hormone + Avandia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NucleomaxX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EG005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant IGF-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eutrophill - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polyacrylamide Hydrogel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIV-Associated Lipodystrophy Syndrome Therapeutics – Drug Profile Updates
HIV-Associated Lipodystrophy Syndrome - Featured News
Jul 05, 2011: Theratechnologies Announces Filing Of Application For Registration Of Tesamorelin In Israel By Sanofi
Jun 06, 2011: Theratechnologies Announces Filing Of European Marketing Authorization Application For Tesamorelin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for HIV-Associated Lipodystrophy Syndrome, Q3 2011
Products under Development for HIV-Associated Lipodystrophy Syndrome – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Ark Therapeutics Group plc, 2011
Zydus Cadila Healthcare Limited, 2011
Theratechnologies Inc., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
HIV-Associated Lipodystrophy Syndrome Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for HIV-Associated Lipodystrophy Syndrome, Q3 2011
Products under Development for HIV-Associated Lipodystrophy Syndrome – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011